Real-World Efficacy and Safety of Ixekizumab from the Joint Psoriasis-Psoriatic Arthritis Clinic (PPAC)
Clinical and Experimental Dermatology · 2026
DOI: 10.1093/ced/llag055 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2026. Verfasst von Aristeidis G Vaiopoulos und 16 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Dermatology-Venereology, National and Kapodistrian University of Athens, Andreas Sygros Hospital, Athens, Greece. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Arthritis, Psoriatic, Psoriasis, Dermatologic Agents.
Abstract (Originalsprache)
Psoriasis and psoriatic arthritis (PsA) are chronic inflammatory diseases, affecting patients’ quality of life, particularly when involving difficult-to-treat areas. While randomized controlled trials (RCTs) have shown that ixekizumab is effective for psoriatic disease, real-world evidence (RWE) is essential for assessing its broader applicability. This retrospective, single-center study evaluated the effectiveness and safety of ixekizumab in 37 Greek patients with psoriasis and/or PsA, including involvement of difficult-to-treat areas, over 52 weeks of treatment. Ixekizumab led to significant and sustained improvements in skin disease up to week 52. Joint manifestations and difficult sites showed marked improvement, as did patient-reported quality of life. Biologic-naïve patients and those with early disease onset showed better responses. No serious adverse events were reported, and cardiovascular parameters remained stable. These findings support ixekizumab’s strong efficacy and safety in routine clinical use, including patients with prior biologic exposure and complex disease, reinforcing its role as a cornerstone therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- First Department of Dermatology-Venereology, National and Kapodistrian University of Athens, Andreas Sygros Hospital, Athens, Greece.
- Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, Attikon University Hospital, Athens, Greece.
- Second Department of Dermatology and Venereorology, Attikon University General Hospital, School of Medicine, National and Kapodistrian University of Athens, Greece.
- Second Department of Cardiology, Attikon University General Hospital, School of Medicine, National and Kapodistrian University of Athens, Greece.
ORCID-Profile: Antonios Kanelleas
Zitieren
APA
Vaiopoulos, A. G., Katsimbri, P., Lazarou-Athanasopoulou, V., Tzavara, C., Theodoropoulos, K., Theotokoglou, S., Kanelleas, A., Syrmali, A., Lampadaki, K., Katsifis-Nezis, D., Sabatakaki, E., Tseronis, D., Zoupidou, K., Pavlidis, G., Ikonomidis, I., Katoulis, A., & Papadavid, E. (2026). Real-World Efficacy and Safety of Ixekizumab from the Joint Psoriasis-Psoriatic Arthritis Clinic (PPAC). Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llag055
Vancouver
Vaiopoulos AG, Katsimbri P, Lazarou-Athanasopoulou V, Tzavara C, Theodoropoulos K, Theotokoglou S, et al. Real-World Efficacy and Safety of Ixekizumab from the Joint Psoriasis-Psoriatic Arthritis Clinic (PPAC). Clinical and Experimental Dermatology. 2026. doi:10.1093/ced/llag055
BibTeX
@article{Vaiopoulos2026,
author = {Vaiopoulos, Aristeidis G and Katsimbri, Pelagia and Lazarou-Athanasopoulou, Vicky and Tzavara, Charikleia and Theodoropoulos, Konstantinos and Theotokoglou, Sofia and Kanelleas, Antonios and Syrmali, Anna and Lampadaki, Kyriaki and Katsifis-Nezis, Dimitrios and Sabatakaki, Elena and Tseronis, Dimitrios and Zoupidou, Konstantina and Pavlidis, George and Ikonomidis, Ignatios and Katoulis, Alexander and Papadavid, Evangelia},
title = {Real-World Efficacy and Safety of Ixekizumab from the Joint Psoriasis-Psoriatic Arthritis Clinic (PPAC)},
journal = {Clinical and Experimental Dermatology},
year = {2026},
doi = {10.1093/ced/llag055}
}
EUVIMED